STOCK TITAN
  1. Home
  2. News
  3. THAR

Tharimmune, Inc. - $THAR STOCK NEWS

Welcome to our dedicated page for Tharimmune news (Ticker: $THAR), a resource for investors and traders seeking the latest updates and insights on Tharimmune stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Tharimmune's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Tharimmune's position in the market.

News
Tharimmune To Participate in Two Upcoming Investor Conferences in May
Rhea-AI Summary

Tharimmune, Inc. (NASDAQ:THAR) will participate in two investor conferences in May. Randy Milby, CEO, will present at the Planet MicroCap Showcase: VEGAS 2024 and attend the EF Hutton Annual Global Conference. Investors can register online to meet with the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.28%
Tags
conferences
-
News
Tharimmune Announces Option Agreement for Key Technologies for Generating HER2/HER3 Antibody Drug Conjugates (ADCs)
Rhea-AI Summary
Tharimmune, a clinical-stage biotechnology company, announced an option agreement with Washington University to develop HER2/HER3 antibody drug conjugates. The technology focuses on human HER2 antibodies, complementing Tharimmune's pipeline of novel antibodies. Prof. Schreiber from Washington University highlighted the importance of targeting HER2, a well-studied tumor marker. Tharimmune aims to develop antibodies targeting HER2 and HER3, potentially creating innovative combination therapies. The agreement enhances Tharimmune's early-stage pipeline by incorporating cutting-edge technology from Washington University, known for its expertise in medicine and biomedical research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.43%
Tags
none
-
News
Tharimmune Announces Scientific Advisory Board to Drive Clinical-Stage Lead in Chronic Liver Disease and Early-Stage Tunable Knob Domains for Generating Antibody Drug Conjugate (ADC) Biotherapeutics
Rhea-AI Summary
Tharimmune forms a Scientific Advisory Board to drive clinical-stage lead in chronic liver disease and early-stage tunable Knob domains for generating Antibody Drug Conjugate (ADC) Biotherapeutics. The board includes experts in immunology, liver diseases, protein engineering, and ADCs to advance therapeutic candidates in inflammation & immunology.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.23%
Tags
management
News
Tharimmune to Present at the Emerging Growth Conference on March 7, 2024
Rhea-AI Summary
Tharimmune, a clinical-stage biotechnology company (NASDAQ: THAR), is set to present at the Emerging Growth Conference on March 7, 2024. The presentation by Chairman and CEO Randy Milby will provide insights into the company's therapeutic candidates in inflammation & immunology. Investors and analysts can engage with the management team in real-time during the event.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.08%
Tags
conferences
-
News
Tharimmune Announces Positive Results in Phase 1 Clinical Trial of TH104, its Lead Clinical Therapeutic Candidate
Rhea-AI Summary
Tharimmune, Inc. (NASDAQ:THAR) announces successful completion of Phase 1 clinical trial for TH104, a transmucosal buccal film for liver-related conditions. Positive safety and tolerability profile demonstrated, with mild side effects. Phase 2 study for chronic pruritus in PBC on-track for 2024 initiation. Company well-funded till 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.26%
Tags
clinical trial
-
News
Tharimmune Announces Dosing of First Patient in Phase 1 Clinical Trial of TH104, its Lead Candidate for Pruritus in Primary Biliary Cholangitis
Rhea-AI Summary
Tharimmune, Inc. (NASDAQ:THAR) has completed dosing the first patient in the Phase 1 clinical trial of TH104, a proprietary transmucosal buccal film designed for liver-related and pruritogenic inflammatory conditions. The trial aims to assess safety, tolerability, and absolute bioavailability of TH104, with topline data expected in 2Q24. The company is fully funded until 2025 and anticipates full readouts of Phase 1 and 2 in moderate-to-severe chronic pruritus in PBC in 4Q24/1Q25.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.82%
Tags
clinical trial
News
Tharimmune Announces Initiation of Phase 1 Clinical Trial of TH104 and Provides Business Update
Rhea-AI Summary
Tharimmune, Inc. (NASDAQ:THAR) announces Phase 1 trial initiation for TH104, a potential treatment for liver-related and pruritogenic inflammatory conditions. The company plans to engage in Phase 2 trials for moderate-to-severe chronic pruritus in PBC patients and outlines a near-clinical pipeline for immuno-oncology targets. Tharimmune is fully funded into 2025 with Phase 1 and Phase 2 results expected in 4Q24/1Q25.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
clinical trial
-
News
Tharimmune Announces Positive Topline Data with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Chronic Liver Disease Patients
Rhea-AI Summary
Tharimmune, Inc. (Nasdaq: THAR) announced positive phase 1 data for TH104, showing a 33.3% decrease in 24-hour mean itching intensity score after a single dose. The company is well-funded into early 2025 and expects bridging PK data in the US and Phase 2a results for chronic pruritus in primary biliary cholangitis (PBC) in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.14%
Tags
none
-
News
Tharimmune, Inc. Announces Closing of $11 Million Public Offering
Rhea-AI Summary
Tharimmune, Inc. (Nasdaq:THAR) closed a public offering of 11,000,000 shares of common stock, raising approximately $11 million. The net proceeds will be used for the advancement of TH104's phase 2 trial expected in 2024, working capital, and other general corporate purposes. ThinkEquity acted as the sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.19%
Tags
offering
News
Tharimmune, Inc. Announces Pricing of $10 Million Public Offering
Rhea-AI Summary
Tharimmune, a clinical-stage biotechnology company (NASDAQ:THAR), announced the pricing of an underwritten public offering of 10,000,000 shares of common stock at a public offering price of $1.00 per share, resulting in gross proceeds of $10,000,000. The company intends to use the net proceeds for the advancement of TH104's phase 2 trial expected in 2024, as well as for working capital and other general corporate purposes. ThinkEquity is acting as sole book-running manager for the offering.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-72.36%
Tags
offering
Stock THAR logo
Tharimmune, Inc.

Nasdaq:THAR

THAR Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

THAR Stock Data

4.45M
11.53M
1.8%
1.16%
0.64%
Research and Development in Biotechnology
Professional, Scientific, and Technical Services
Link
United States of America
BRIDGEWATER